• Age ≥18 years, and life expectancy\>12 weeks

• Weight: \>30kg

• Histologically proven locally advanced or metastatic/unresectable cholangiocarcinoma

• Documentation of RECISTv1.1 measurable disease

• Must not have had radiologic progression after 6-8 cycles of gemcitabine and cisplatin and durvalumab

• Adequate haematological and end-organ function as defined by the following parameters:

∙ Haemoglobin ≥ 90g/L (without a transfusion in the past two weeks)

‣ Platelets ≥100 x 109/L (without a transfusion in the past two weeks)

‣ Neutrophils ≥ 1.0 x 109/L (without the use of G-CSF in the 4 weeks prior to first dose)

‣ ALT/AST \<3x ULN irrespective of presence of liver metastases

‣ Serum bilirubin ≤ 1.5x ULN except in cases of known Gilbert's Syndrome where total bilirubin must be \<4x ULN

‣ Albumin ≥ 25 g/L

‣ Serum Creatinine ≤1.5 x ULN or eGFR ≥ 30mL/min/1.73m2 as calculated by Cockcroft Gault Equation

• Able to swallow oral medications without any difficulties or medical history associated with malabsorption or any conditions that may impact on compliance or absorption of the study treatment.

• Women of Childbearing potential must be either totally abstinent or agree to use at least one highly effective method of birth control (e.g., oral contraceptive pill, barrier method) for the duration of the study and for at least 6 months after the final dose of study medication. They must also have a negative serum beta-hCG in the 7 days prior to first dose of study drug.

• Non-sterile males and their female partners must also either be totally abstinent or agree to use at least one highly effective method of birth control (e.g., oral contraceptive pill, barrier method) for the duration of the study and for at least 6 months after the final dose of study medication.

⁃ Patient is willing and able to comply with the protocol for the duration of the study, including undergoing treatment and scheduled visits and examinations including follow up.

⁃ Capable of giving signed informed consent, which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol. Written informed consent and any locally required authorization obtained from the patient/legal representative prior to performing any protocol-related procedures, including screening evaluations.